Clover Health Investments (CLOV) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic Achievements and Financial Performance

• Achieved material Adjusted EBITDA profitability for 2024 without raising capital, meeting a key goal set the previous year.

• Reported 27% year-over-year Medicare Advantage membership growth as of January 2025, reaching approximately 100,000 members, with 95% enrolled in 4-Star plans.

• Secured double upgrades in Star Ratings, reaching 3.5 stars for 2025 and 4 stars for payment year 2026 for flagship PPO plans.

• Maintained strong loss ratios and reinvested superior margins into member benefits, sustaining plan richness despite industry pressures; MCR at 75.6% and BER at 80.6% as of Q3 2024.

• Majority of new members were switchers from other MA plans, with high retention and favorable cohort dynamics.

Technology and Care Model Innovation

• Launched Counterpart Health, a subsidiary focused on R&D and technology, making the Clover Assistant platform available to third-party Medicare Advantage entities and generating new SaaS and tech-enabled revenue streams.

• Clover Assistant leverages AI and over 100 proprietary models to synthesize data from more than 100 sources, providing actionable insights to physicians, including those outside the company’s network.

• Focused on empowering wide-network PCPs with AI-driven recommendations, improving early identification and management of chronic diseases.

• Unique approach avoids value-based contracts, instead compensating physicians for time spent using the platform, driving quality improvements on a fee-for-service basis.

• Expanded home care footprint in Georgia, targeting high-acuity members and integrating in-home primary care with data sharing to external PCPs.

Clinical Outcomes and Quality Measures

• PPO plan ranked number one nationally for HEDIS clinical quality scores among large plans, achieving a 4.94/5 score for 2025; HMO ranked number two.

• Outperformed national medians on key readmission prevention and care transition measures by 300–2,800 basis points, achieving five-star performance.

• Technology-driven care model credited for high Star Ratings and improved clinical outcomes, especially in chronic disease management.

• AI-powered insights have led to earlier identification and management of diabetes and CKD, reducing total cost of care.

• Medication adherence improved by 5% on the day of a Clover Assistant visit and remained 3% higher 90 days post-visit.